Advanced search    

Search: authors:"Namyi Gu"

4 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers

Clinical pharmacology and Therapeutics, Kyung Hee University College of Medicine and Hospital , Seoul 2 namyi Gu Department of Clinical pharmacology and Therapeutics, Dongguk University College of Medicine

The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan

The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan Namyi Gu,1,2 Joo-Youn Cho,3 Kwang-Hee Shin,4 In-Jin Jang,3 Moo-Yong Rhee2,5 1Department of Clinical

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers Namyi Gu,1,3,* Min Kyu Park,1,4,* Tae-Eun Kim,1,5 Mi

Intravenous Amantadine for Freezing of Gait Resistant to Dopaminergic Therapy: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Clinical Trial

Background Freezing of gait (FOG) is one of the most disabling symptoms in Parkinsonism. Open-label studies have suggested that intravenous (IV) amantadine is effective against FOG resistant to dopaminergic therapy in Parkinson's disease (PD). We evaluated the efficacy of IV amantadine on FOG resistant to dopaminergic therapy. Methodology/Principal Findings This was a randomized...